* Taro Pharmaceutical Industries Ltd TARO.N TARO.K is
expected
to show a rise in quarterly revenue when it reports results on
May 23.
* The Haifa Israel-based company is expected to report a
0.2% increase in revenue to $139.202 million from $138.98
million a year ago, according to the estimate from one analyst,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Taro Pharmaceutical
Industries Ltd is for earnings of 19 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Taro
Pharmaceutical Industries Ltd is $35, above its last closing
price of $28.98.
This summary was machine generated May 19 at 20:16 GMT. All
figures in US dollars unless otherwise stated